Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1β administration

Neuropharmacology

Volumn 54, Issue 3, 2008, Pages 509-520

  Whitaker, Keith W ^a   Reyes, Teresa M ^b  

^a Department of Biochemistry ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fos; HS014; Interlukin 1; Paraventricular; Sickness behavior

Indexed keywords

BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; INTERLEUKIN 1BETA; MELANOCORTIN RECEPTOR; PROTEIN C FOS; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTERIOR HYPOTHALAMUS; APPETITE; ARTICLE; ATTENUATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; LUNG GAS EXCHANGE; MALE; METABOLIC RATE; METABOLISM; NERVE BLOCK; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ANIMALS; BEHAVIOR, ANIMAL; DRINKING; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; EATING; INTERLEUKIN-1BETA; LOCOMOTION; MALE; ONCOGENE PROTEINS V-FOS; OXYGEN CONSUMPTION; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MELANOCORTIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38749123510     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.014     Document Type: Article

References (42)

1. Bagnol D., Lu X.-Y., Kaelin C.B., Day H.E., Ollmann M., Gantz I., Akil H., Barsh G.S., and Watson S.J. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J. Neurosci. 19 (1999) RC26
2. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., and Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur. J. Neurosci. 12 (2000) 4447-4456
3. Boddaert M.S., Gerritsen W.R., and Pinedo H.M. On our way to targeted therapy for cachexia in cancer?. Curr. Opin. Oncol. 18 (2006) 335-340
4. Bodnar R.J., Pasternak G.W., Mann P.E., Paul D., Warren R., and Donner D.B. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res. 49 (1989) 6280-6284
5. Brebner K., Hayley S., Zacharko R., Merali Z., and Anisman H. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 22 (2000) 566-580
6. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., Rosenblum C.I., Vongs A., Feng Y., Cao L., Metzger J.M., Strack A.M., Camacho R.E., Mellin T.N., Nunes C.N., Min W., Fisher J., Gopal-Truter S., MacIntyre D.E., Chen H.Y., and van de Ploeg L.H. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26 (2000) 97-102
7. Cowley M.A., Pronchuk N., Fan W., Dinulescu D.M., Colmers W.F., and Cone R.D. Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 24 (1999) 155-163
8. DeBoer M.D., and Marks D.L. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol. Metab. 17 (2006) 199-204
9. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Engstrom P.F., Ezdinli E.Z., Horton J., Johnson G.J., Moertel C.G., Oken M.M., Perlia C., Rosenbaum C., Silverstein M.N., Skeel R.T., Sponzo R.W., and Tormey D.C. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69 (1980) 491-497
10. Ericsson A., Kovacs K.J., and Sawchenko P.E. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J. Neurosci. 14 (1994) 897-913
11. Ericsson A., Liu C., Hart R.P., and Sawchenko P.E. Type I interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 361 (1995) 681-698
12. Fearon K.C., Voss A.C., Hustead D.S., and Group C.C.S. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83 (2006) 1345-1350
13. Forbes S., Bui S., Robinson B.R., Hochgeschwender U., and Brennan M.B. Integrated control of appetite and fat metabolism by the leptin-proopiomelanocortin pathway. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4233-4237
14. Hayley S., Staines W., Merali Z., and Anisman H. Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-[alpha]. Neuroscience 106 (2001) 137-148
15. Hoggard N., Rayner D.V., Johnston S.L., and Speakman J.R. Peripherally administered [Nle4,D-Phe7]-{alpha}-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice. J. Mol. Endocrinol. 33 (2004) 693-703
16. Huang Q.-H., Hruby V.J., and Tatro J.B. Role of central melanocortins in endotoxin-induced anorexia. Am. J. Physiol. 276 (1999) R864-R871
17. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., Gu W., Kesterson R.A., Boston B.A., Cone R.D., Smith F.J., Campfield L.A., Burn P., and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1997) 131-141
18. Joppa M.A., Ling N., Chen C., Gogas K.R., Foster A.C., and Markison S. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia. Peptides 26 (2005) 2294-2301
19. Laviano A., Meguid M.M., Inui A., Muscaritoli M., and Rossi-Fanelli F. Therapy Insight: cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat. Clin. Pract. Oncol. 2 (2005) 158-165
20. Lawrence C.B., and Rothwell N.J. Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat. J. Neuroendocrinol. 13 (2001) 490-495
21. Leon L.R., Whi A.A., and Kluger M.J. Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am. J. Physiol. 275 (1998) R269-R277
22. Ling P.R., Schwartz J.H., and Bistrian B.R. Mechanisms of host wasting induced by administration of cytokines in rats. Am. J. Physiol. 272 (1997) E333-E339
23. Ludwig D.S., Mountjoy K.G., Tatro J.B., Gillette J.A., Frederich R.C., Flier J.S., and Maratos-Flier E. Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am. J. Physiol. Endocrinol. Metab. 274 (1998) E627-E633
24. Markison S., Foster A.C., Chen C., Brookhart G.B., Hesse A., Hoare S.R.J., Fleck B.A., Brown B.T., and Marks D.L. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146 (2005) 2766-2773
25. Marks D.L., Ling M., and Cone R.D. Role of the central melanocortin system in cachexia. Cancer Res. 61 (2001) 1432-1438
26. Morgan M.M., Clayton C.C., and Heinricher M.M. Simultaneous analysis of the time course for changes in core body temperature, activity, and nociception following systemic administration of interleukin-1[beta] in the rat. Brain Res. 996 (2004) 187-192
27. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., and Cone R.D. Localization of the melanocortin-4 (MCR-4) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 8 (1994) 1298-1308
28. Nadeau S., and Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 93 (1999) 1449-1464
29. Plata-Salaman C.R. Cytokines and anorexia: a brief overview. Semin. Oncol. 25 (1998) 64-72
30. Reyes T.M., and Sawchenko P.E. Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. J. Neurosci. 22 (2002) 5091-5099
31. Roselli-Rehfuss L., Mountjoy K.G., Robbins L.S., Mortrud M.T., Low M.J., Tatro J.B., Entwistle M.L., Simerly R.B., and Cone R.D. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8856-8860
32. Rossi M., Kim M.S., Morgan D.G.A., Small C.J., Edwards C.M.B., Sunter D., Abusnana S., Goldstone A.P., Russell S.H., Stanley S.A., Smith D.M., Yagaloff K., Ghatei M.A., and Bloom S.R. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 139 (1998) 4428-4431
33. Sawchenko P.E. Toward a new neurobiology of energy balance, appetite, and obesity: the anatomists weigh in. J. Comp. Neurol. 402 (1998) 435-441
34. Small C.J., Liu Y.L., Stanley S.A., Connoley I.P., Kennedy A., Stock M.J., and Bloom S.R. Chronic CNS administration of Agouti-related protein (Agrp) reduces energy expenditure. Int. J. Obes. 27 (2003) 530-533
35. Somm E., Henrichot E., Pernin A., Juge-Aubry C.E., Muzzin P., Dayer J.-M., Nicklin M.J.H., and Meier C.A. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 54 (2005) 3503-3509
36. Swiergiel A.H., and Dunn A.J. Feeding, exploratory, anxiety- and depression-related behaviors are not altered in interleukin-6-deficient male mice. Behav. Brain Res. 171 (2006) 94-108
37. Tisdale M.J. Biology of cachexia. J. Natl. Cancer Inst. 89 (1997) 1763-1773
38. Tolchard S., Hare A.S., Nutt D.J., and Clarke G. TNF[alpha] mimics the endocrine but not the thermoregulatory responses of bacterial lipopolysaccharide (LPS): Correlation with FOS-expression in the brain. Neuropharmacology 35 (1996) 243-248
39. Veltri S., and Smith J.W. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Oncologist 1 (1996) 190-200
40. Wieczorek M., and Dunn A.J. Relationships among the behavioral, noradrenergic, and pituitary-adrenal responses to interleukin-1 and the effects of indomethacin. Brain Behav. Immun. 20 (2006) 477-487
41. Wisse B.E., Frayo R.S., Schwartz M.W., and Cummings D.E. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142 (2001) 3292-3301
42. Wisse B.E., Ogimoto K., and Schwartz M.W. Role of hypothalamic interleukin-1[beta] (IL-1[beta]) in regulation of energy homeostasis by melanocortins. Peptides 27 (2006) 265-273